Genmab — Januar 2021
-
Horizon Therapeutics plc Provides Preliminary 2020 Financial Results https://www.businesswire.com/news/home/20210111005295/en/Horizon-Therapeutics-plc-Provides-Preliminary-2020-Financial-Results-Exceeding-Full-Year-2020-Net-Sales-and-Adjusted-EBITDA-Guidance-Provides-Update-on-TEPEZZA
-teprotumumab-trbw-Supply-and-New-KRYSTEXXA-pegloticase-injection-Trials#.X_xCc5v9fgw.twitter -
small new The DART Study- Daratumumab Treatment in ITP https://clinicaltrials.gov/ct2/show/NCT04703621
-
Genmab
@Genmab
·
2 t
Don’t miss us at #JPM21 on Jan 13 at 10 AM ET/ 4 PM CET! We’ll be discussing highlights of our #oncology research, innovative pipeline and priorities for 2021. https://jpmorgan.metameetings.net/events/healthc -
Det her er vist bedre: https://jpmorgan.metameetings.net/events/healthcare21/general_signin
-
-
-
God morgen.
-
Tirsdagens danske avisuddrag med DI, Vaccinepas og Coloplasthttps://www.proinvestor.com/investornyt/671005/tirsdagens-danske-avisuddrag-med-di-vaccinepas-og-coloplast
-
Johnson & Johnson (JNJ) CEO Alex Gorsky Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript) https://seekingalpha.com/article/4398411-johnson-johnson-jnj-ceo-alex-gorsky-presents-39th-annual-jpmorgan-virtual-healthcare
-
Next is about the pipeline that we have. More than 10 compounds that we expect to file or launch over the next several years, all of which have more than a $1 billion worth of potential. These are really exciting areas certainly in areas such as oncology. For example the CD3s, both the CD3 and BCMA CD3 that we have and things like multiple myeloma. If you look at what we have in immunology, of course, the recent addition of Momenta, we're very excited about that as well.
-
Just maybe double down on what Alex says, there are some very excited – exciting assets in the pipeline that we have just recently filed are in the process of being filed I think of amivantamab for small cell lung cancer. We filed that I think was early December for monotherapy. We look to combine that with lazertinib to have a bigger impact in non-small cell lung cancer.
-
Refinitiv Eikon screenshot: News: NCC to develop and build new headquarters for Genmab at Kontorværket in Copenhagen - CIS | News Wires | Refinitiv Eikon
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind